Clinical Trials Browser

Phase 1 × Terminated × durvalumab × Clear all

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04613492 2025-06-24

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Phase 1 Terminated

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT04108481 2025-03-28

iRE-C

Phase 1 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05911308 2025-03-21

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04287894 2024-11-06

Induction

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04348292 2024-08-22

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Phase 1 Terminated

3 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03199040 2024-05-28

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Phase 1 Terminated

18 enrolled 9 charts

Triple Negative Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT03275597 2023-05-15

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 1 Terminated

6 enrolled 11 charts

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

NCT03665129 2022-01-27

STELLAR-001

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Phase 1 Terminated

13 enrolled 15 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Phase 1 Terminated

9 enrolled 13 charts

Other solid neoplasm

Solid Tumor

NCT02556463 2018-12-19

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Phase 1 Terminated

Neoplasms